Clinical trial
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00091338 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00091338 |
|---|---|
| Title | Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | A Study of Subcutaneous "CYT 99 007" (Interleukin-7) in Conjunction With Peptide Immunization in Patients With Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-7 |
| Start date | Aug 1, 2004 |
| First posted | Sep 9, 2004 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: